Treprostinil
CAS No. 81846-19-7
Treprostinil( LRX-15 | Orenitram | Remodulin )
Catalog No. M19938 CAS No. 81846-19-7
Treprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 35 | In Stock |
|
5MG | 65 | In Stock |
|
10MG | 110 | In Stock |
|
25MG | 259 | In Stock |
|
50MG | 434 | In Stock |
|
100MG | 620 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTreprostinil
-
NoteResearch use only, not for human use.
-
Brief DescriptionTreprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
-
DescriptionTreprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
-
In VitroTreprostinil has high affinity for the DP1, EP2 and IP receptors (Ki=4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries.Treprostinil inhibits viability of cultured endothelial colony forming cells. Endothelial colony forming cells proliferation is stimulated by conditioned media from Treprostinil pretreated mesenchymal stem cells.
-
In VivoInhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH). Treprostinil preserves the sinusoidal endothelial cell lining and reduces platelet deposition early post-transplantation compared to placebo. Hepatic tissue blood flow is significantly compromised in the placebo group, whereas treprostinil maintains blood flow similar to normal levels.Treprostinil treatment significantly increases the vessel-forming ability of endothelial colony forming cells combined with mesenchymal stem cells in Matrigel implanted in nude mice. Silencing VEGF-A gene in mesenchymal stem cells also blocks the pro-angiogenic effect of Treprostinil. Treprostinil is most efficacious in raising intracellular cAMP levels in murine and human hematopoietic stem and progenitor cells. Treatment with Treprostinil significantly reduces the recruitment of cells compared to normoxic mice. Treprostinil also reduces right ventricular systolic pressure and slightly reduces the vascular remodelling but fails to reverse the right ventricular hypertrophy.
-
SynonymsLRX-15 | Orenitram | Remodulin
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorDP1 IP EP2
-
Research AreaCardiovascular Disease
-
IndicationPulmonary hypertension
Chemical Information
-
CAS Number81846-19-7
-
Formula Weight390.51
-
Molecular FormulaC23H34O5
-
Purity>98% (HPLC)
-
SolubilityDMSO: 40 mg/mL;Ethanol: 20 mg/mL
-
SMILESCCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Whittle BJ et al. Binding and activity of the prostacyclin receptor (IP) agonists treprostinil and iloprost at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84(1):68-75.
molnova catalog
related products
-
4-Oxofenretinide
4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis.
-
AH 6809
AH 6809 is an antagonist of EP and DP receptor(with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively).
-
MF-766
MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research.